The reaffirmation of an Outperform rating and a steady price target by a reputable analyst like Jay Olson from Oppenheimer is likely to instill confidence among investors and could positively influence Sutro Biopharma's stock price in the short term. Analyst ratings, especially those that are positive, tend to have a favorable impact on stock prices as they often lead to increased investor interest.